Prévisions du marché des maladies cardiométaboliques en Asie-Pacifique jusqu’en 2028 – Impact du COVID-19 et analyse régionale par type (maladie cardiovasculaire (MCV), diabète de type 2, hypertension et obésité), traitement (inhibiteurs de l’ECA, diurétiques, glucophage et autres), posologie ( comprimé et injection), voie d\'administration (orale et intraveineuse), utilisateurs finaux (établissements hospitaliers, cliniques et de soins à domicile) et canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne)

Introduction au marché

La maladie cardiométabolique est caractérisée par un groupe d\'anomalies et de symptômes qui soulèvent le risque que les individus développent une maladie cardiovasculaire. L\'hypertension, l\'obésité, la résistance à l\'insuline, la dyslipidémie, un mauvais profil de cholestérol (LDL) et une tolérance au glucose sont quelques-uns des symptômes. Les personnes souffrant du syndrome cardiométabolique sont sujettes à plusieurs autres maladies potentiellement mortelles telles que le diabète de type 2, les accidents vasculaires cérébraux, les maladies coronariennes (MAC), les maladies cardiovasculaires (MCV) et bien d\'autres.

De plus, la prévalence croissante des maladies cardiométaboliques devrait soutenir la croissance du marché au cours de la période de prévision. Cependant, le sous-diagnostic des maladies cardiovasculaires dans les pays à revenu faible et intermédiaire (PRFI) limite la croissance du marché des maladies cardiométaboliques en Asie-Pacifique.

Les perturbations de la chaîne d\'approvisionnement et la demande massive de des traitements efficaces pour le traitement du COVID-19 ont placé le secteur de la recherche en soins de santé dans une situation cruciale dans la région Asie-Pacifique. Des mesures prohibitives ont été prises pour contrôler la propagation de cette pandémie. La pandémie de COVID-19 a largement touché les économies de la région Asie-Pacifique. Des pays comme l’Inde (31 769 132), le Japon (956 407), la Chine (93 289) et la Corée du Sud (203 926) ont été durement touchés par la pandémie. La situation socio-économique a été gravement affectée, avec une inflation négative, un PIB négatif et une hausse du chômage dans la région. Récemment, le nombre de patients souffrant à la fois d\'hypertension et d\'obésité a augmenté au Japon. Ces patients courent un risque exceptionnellement élevé de développer une maladie grave liée au COVID-19 et nécessitent donc une observation attentive et un traitement intensif. Comparable à l’hypertension, la définition de l’obésité n’est pas constante selon les études/pays, ce qui nécessite d’être pris en considération. Cependant, il est essentiel de noter que le mécanisme thérapeutique du CCB contre le COVID-19 attend encore des recherches plus approfondies et des essais cliniques contrôlés randomisés.

Aperçu du marché et Dynamics

Le marché des maladies cardiométaboliques en Asie-Pacifique devrait atteindre 28 953,2 millions de dollars américains d\'ici 2028, contre 21 091,3 millions de dollars américains en 2021 ; il devrait croître à un TCAC de 4,6 % entre 2021 et 2028. Les maladies cardiométaboliques (CMD) sont l’une des principales causes de décès dans le monde. Ces maladies sont principalement causées par un mode de vie malsain, la sédentarité, le tabagisme et une mauvaise alimentation. Les CMD comprennent les maladies cardiovasculaires (MCV), le diabète sucré et l\'insuffisance rénale chronique. La plupart des maladies cardiovasculaires peuvent être évitées en s’attaquant aux facteurs de risque comportementaux, tels que la consommation de tabac, les choix alimentaires malsains, l’obésité, l’inactivité physique et la consommation d’alcool. Le diabète est l’une des maladies chroniques potentiellement mortelles pour lesquelles il n’existe aucun remède fonctionnel. Cela entraîne diverses complications et augmente le risque global de décès prématuré. Les crises cardiaques, les accidents vasculaires cérébraux, l\'insuffisance rénale, l\'amputation d\'une jambe, la perte de vision et les lésions nerveuses sont les principales complications associées au diabète. On constate une augmentation du nombre de personnes souffrant d\'un ou plusieurs DMC en raison de l\'augmentation du tabagisme, du manque d\'exercice, de la consommation d\'alcool et de mauvaises habitudes alimentaires. La prévalence croissante de l’obésité fait que de nombreux patients souffrent également de DMC. Avec cette augmentation rapide de la prévalence des maladies cardiométaboliques, le besoin de traitements appropriés contre les maladies cardiométaboliques est monté en flèche, entraînant une croissance considérable du marché des maladies cardiométaboliques en Asie-Pacifique.

< u>Segments clés du marché

En termes de type, le segment des maladies cardiovasculaires représentait la plus grande part du marché des maladies cardiométaboliques en Asie-Pacifique en 2020. En termes de traitement, le segment des inhibiteurs de l\'ECA représentait la plus grande part du marché des maladies cardiométaboliques de l\'Asie-Pacifique en 2020. En termes de dosage, le segment des comprimés représentait la plus grande part du marché des maladies cardiométaboliques de l\'Asie-Pacifique en 2020. de voie d\'administration, le segment oral représentait la plus grande part du marché des maladies cardiométaboliques en Asie-Pacifique en 2020. En termes d\'utilisateur final, le segment hospitalier représentait la plus grande part du marché des maladies cardiométaboliques en Asie-Pacifique en 2020. En outre, sur la base En ce qui concerne le canal de distribution, le segment de la pharmacie hospitalière détenait la plus grande part de marché en 2020.

Principales sources et sociétés répertoriées

Quelques sources primaires et secondaires majeures mentionnées pour la préparation de ce rapport sur le marché des maladies cardiométaboliques en Asie-Pacifique sont les sites Web des entreprises, les rapports annuels et les rapports financiers. , des documents gouvernementaux nationaux et une base de données statistiques, entre autres. Les principales sociétés répertoriées dans le rapport sont Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Cardax Inc. et Kowa Company, Ltd.

Rapport sur les raisons d\'acheter

Comprendre le paysage du marché des maladies cardiométaboliques en Asie-Pacifique et identifier les segments de marché susceptibles de garantir un fort retour
Pour comprendre le paysage du marché en constante évolution et rester en avance sur la concurrence
Planifier efficacement les fusions, acquisitions et accords de partenariat sur le marché des maladies cardiométaboliques en Asie-Pacifique en identifiant les segments avec les ventes probables les plus prometteuses
Prendre des décisions commerciales éclairées à partir d\'une analyse perspicace et complète des performances du marché de divers segments
Pour obtenir des prévisions de revenus du marché de la région Asie-Pacifique Marché des maladies cardiométaboliques basé sur divers segments pour la période 2021-2028

SEGMENTATION DU MARCHÉ DES MALADIES CARDIOMÉTABOLIQUES EN ASIE-PACIFIQUE

Par Type

Maladie cardiovasculaire (MCV)
Diabète de type 2
Hypertension
Obésité

Par traitement

Inhibiteurs de l\'ECA
Diurétiques
Glucophage
Autres

Par dosage

Comprimé
Injection

Par voie d\'administration

Oral
Intraveineux

Par les utilisateurs finaux

Hôpital
Clinique
Paramètres de soins à domicile ;

Par canal de distribution

Pharmacie hospitalière
- Pharmacie hospitalière
- Pharmacie de détail
- Pharmacie en ligne
Par pays
- Asie-Pacifique
- Chine
- Japon
- Inde
- Corée du Sud
- Australie
- Reste de l\'Asie-Pacifique
Entreprises mentionnées
- Eli Lilly et compagnie.
- Bayer AG
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Cardax, Inc.

1. Introduction 21

1.1 Scope of the Study. 21

1.2 The Insight Partners Research Report Guidance. 21

1.3 Market Segmentation. 23

1.3.7 Asia Pacific Cardiometabolic Diseases market – By Country. 25

2. Asia Pacific Cardiometabolic Diseases Market – Key Takeaways 26

3. Research Methodology 31

3.1 Coverage. 33

3.2 Secondary Research. 33

3.3 Primary Research. 34

4. Asia Pacific Cardiometabolic Diseases Market – Market Landscape 35

4.1 Overview.. 35

4.2 PEST Analysis. 36

4.3 Expert Opinions. 37

5. Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics 38

5.1 Market Drivers. 38

5.1.1 Increasing Prevalence of Cardiometabolic Diseases. 38

5.1.2 Innovation in Cardiometabolic Diseases Therapeutics. 38

5.2 Market Restraints. 39

5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs) 39

5.3 Market Opportunities. 40

5.3.1 Technological Advancements in CMD Diagnosis. 40

5.4 Future Trends. 40

5.4.1 Personalized Treatment for CMDs. 40

5.5 Impact Analysis. 41

6. Asia Pacific Cardiometabolic Diseases Market – Regional Analysis 42

6.1 Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis. 42

7. Asia Pacific Cardiometabolic Diseases Market Analysis – By Type 44

7.1 Overview.. 44

7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

7.3 Cardiovascular Disease (CVD) 45

7.3.1 Overview.. 45

7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 46

7.4 Hypertension. 47

7.4.1 Overview.. 47

7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 47

7.5 Type 2 Diabetes. 48

7.5.1 Overview.. 48

7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 48

7.6 Obesity. 50

7.6.1 Overview.. 50

7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 50

8. Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment 52

8.1 Overview.. 52

8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

8.3 ACE inhibitors. 53

8.3.1 Overview.. 53

8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn) 53

8.4 Diuretics. 55

8.4.1 Overview.. 55

8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 55

8.5 Glucophage. 56

8.5.1 Overview.. 56

8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 56

8.6 Others. 57

8.6.1 Overview.. 57

8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 57

9. Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage 58

9.1 Overview.. 58

9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

9.3 Tablet 59

9.3.1 Overview.. 59

9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 59

9.4 Injection. 60

9.4.1 Overview.. 60

9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn) 60

10. Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration 61

10.1 Overview.. 61

10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

10.3 Oral 62

10.3.1 Overview.. 62

10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn) 62

10.4 Intravenous. 64

10.4.1 Overview.. 64

10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn) 64

11. Asia Pacific Cardiometabolic Diseases Market Analysis – By End User 66

11.1 Overview.. 66

11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

11.3 Clinic. 67

11.3.1 Overview.. 67

11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn) 67

11.4 Hospital 68

11.4.1 Overview.. 68

11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn) 68

11.5 Homecare Settings. 70

11.5.1 Overview.. 70

11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn) 70

12. Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel 72

12.1 Overview.. 72

12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

12.3 Hospital Pharmacy. 73

12.3.1 Overview.. 73

12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 73

12.4 Retail Pharmacy. 74

12.4.1 Overview.. 74

12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 74

12.5 Online Pharmacy. 76

12.5.1 Overview.. 76

12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn) 76

13. Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis 78

13.1 Asia Pacific: Cardiometabolic Diseases Market 78

13.1.1 Overview.. 78

13.1.2 Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 80

13.1.3 Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

13.1.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

13.1.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

13.1.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

13.1.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

13.1.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

13.1.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

13.1.9.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 85

13.1.9.1.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

13.1.15.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.15.1.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 90

13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

13.1.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million) 95

13.1.21.1.1 India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

13.1.27.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.27.1.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 100

13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

13.1.33.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.33.1.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 105

13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

13.1.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 110

13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

14. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 115

14.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic. 115

15. Asia Pacific Cardiometabolic Diseases Market – Industry Landscape 117

15.1 Overview.. 117

15.2 Growth Strategies in the Cardiometabolic Diseases Market (%) 118

15.3 Organic Developments. 119

15.3.1 Overview.. 119

15.4 Inorganic Developments. 122

15.4.1 Overview.. 122

16. Company Profiles 124

16.1 Eli Lilly and Company. 124

16.1.1 Key Facts. 124

16.1.2 Business Description. 124

16.1.3 Products and Services. 125

16.1.4 Financial Overview.. 127

16.1.5 SWOT Analysis. 130

16.1.6 Key Developments. 131

16.2 Bayer AG.. 134

16.2.1 Key Facts. 134

16.2.2 Business Description. 134

16.2.3 Products and Services. 135

16.2.4 Financial Overview.. 135

16.2.5 SWOT Analysis. 138

16.2.6 Key Developments. 139

16.3 Novartis AG.. 141

16.3.1 Key Facts. 141

16.3.2 Business Description. 141

16.3.3 Products and Services. 142

16.3.4 Financial Overview.. 143

16.3.5 SWOT Analysis. 146

16.3.6 Key Developments. 147

16.4 Boehringer Ingelheim International GmbH.. 148

16.4.1 Key Facts. 148

16.4.2 Business Description. 148

16.4.3 Products and Services. 149

16.4.4 Financial Overview.. 150

16.4.5 SWOT Analysis. 154

16.4.6 Key Developments. 155

16.5 Novo Nordisk A/S. 157

16.5.1 Key Facts. 157

16.5.2 Business Description. 157

16.5.3 Products and Services. 158

16.5.4 Financial Overview.. 159

16.5.5 SWOT Analysis. 162

16.5.6 Key Developments. 163

16.6 AstraZeneca. 165

16.6.1 Key Facts. 165

16.6.2 Business Description. 165

16.6.3 Products and Services. 166

16.6.4 Financial Overview.. 167

16.6.5 SWOT Analysis. 170

16.6.6 Key Developments. 171

16.7 Cardax, Inc. 173

16.7.1 Key Facts. 173

16.7.2 Business Description. 173

16.7.3 Products and Services. 174

16.7.4 Financial Overview.. 174

16.7.5 SWOT Analysis. 177

16.7.6 Key Developments. 177

16.8 Kowa Company, Ltd. 178

16.8.1 Key Facts. 178

16.8.2 Business Description. 178

16.8.3 Products and Services. 179

16.8.4 Financial Overview.. 179

16.8.5 SWOT Analysis. 180

16.8.6 Key Developments. 181

17. Appendix 182

17.1 About The Insight Partners. 182

17.2 Glossary of Terms. 183

LIST OF TABLES

Table 1. Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 81

Table 2. Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 81

Table 3. Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 82

Table 4. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 82

Table 5. Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 83

Table 6. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 83

Table 7. China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 86

Table 8. China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 87

Table 9. China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 87

Table 10. China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 88

Table 11. China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 88

Table 12. China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 89

Table 13. Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 91

Table 14. Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 92

Table 15. Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 92

Table 16. Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 93

Table 17. Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 93

Table 18. Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 94

Table 19. India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 97

Table 20. India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 97

Table 21. India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 98

Table 22. India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 98

Table 23. India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 99

Table 24. India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 99

Table 25. South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 101

Table 26. South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 102

Table 27. South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 102

Table 28. South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 103

Table 29. South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 103

Table 30. South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 104

Table 31. Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 106

Table 32. Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 107

Table 33. Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 107

Table 34. Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 108

Table 35. Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 108

Table 36. Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 109

Table 37. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million) 111

Table 38. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million) 112

Table 39. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million) 112

Table 40. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million) 113

Table 41. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million) 113

Table 42. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million) 114

Table 43. Organic Developments in the Cardiometabolic Diseases Market 119

Table 44. Inorganic Developments in the Cardiometabolic Diseases Market 123

Table 45. Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market 183

LIST OF FIGURES

Figure 1. Asia Pacific Cardiometabolic Diseases Market Segmentation. 23

Figure 2. Asia Pacific Cardiometabolic Diseases Market Overview.. 26

Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market 27

Figure 4. Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million) 28

Figure 5. Asia Pacific Cardiometabolic Diseases Market, Industry Landscape. 29

Figure 6. Asia Pacific PEST Analysis. 36

Figure 7. Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints. 41

Figure 8. Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028. 43

Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028) 44

Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 46

Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 47

Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 49

Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 51

Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028) 52

Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 54

Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 55

Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 56

Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 57

Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028) 58

Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 59

Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn) 60

Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%) 61

Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn) 63

Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn) 65

Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%) 66

Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn) 67

Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn) 69

Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn) 71

Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%) 72

Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 73

Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 75

Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn) 77

Figure 33. Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million) 79

Figure 34. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million) 80

Figure 35. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%) 84

Figure 36. China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 86

Figure 37. Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 91

Figure 38. India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 96

Figure 39. South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 101

Figure 40. Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 106

Figure 41. Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million) 111

Figure 42. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market 116

Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%) 118

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement
Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports

Report Name	Published Date
Asia Pacific Wind Turbine Condition Monitoring Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Component (Hardware, and Software an..	May 2022
Asia Pacific Automotive System Simulation Software Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Transmission, Engine, Elec..	May 2022
Asia Pacific Ground Engaging Tools Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Application (Excavators, Loaders, Bulldozers, an..	May 2022

Purchase Options

Single User License

$3000

$1800

Site License

$4000

$2400

Enterprise License

$5000